Ultragenyx Pharmaceutical/RARE

$42.37

-2.32%
-
1D1W1MYTD1YMAX

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Ticker

RARE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Emil Kakkis

Employees

1,276

Headquarters

Novato, United States

RARE Metrics

BasicAdvanced
$3.63B
Market cap
-
P/E ratio
-$8.33
EPS
0.67
Beta
-
Dividend rate
$3.63B
0.66554
$54.98
$31.52
736.63K
2.611
2.49
-39.96%
-193.23%
-48.63%
8.363
13.184
56.101
19.52%
17.66%
17.01%

What the Analysts think about RARE

Analyst Ratings

Majority rating from 20 analysts.
Buy

Price Targets

Average projection from 19 analysts.
112.3% upside
High $140.00
Low $48.00
$42.37
Current price
$89.95
Average price target

RARE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-96.7% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$127.3M
29.9%
Net income
$-123.1M
-22.87%
Profit margin
-96.7%
-40.62%

RARE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.15%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.33
-$2.25
-$2.23
-$1.52
-
Expected
-$1.98
-$2.07
-$2.08
-$1.62
-$1.76
Surprise
17.89%
8.47%
7.31%
-6.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical (RARE) has a market cap of $3.63B as of April 19, 2024.

What is the P/E ratio for Ultragenyx Pharmaceutical stock?

The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of April 19, 2024.

Does Ultragenyx Pharmaceutical stock pay dividends?

No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Ultragenyx Pharmaceutical dividend payment date?

Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.

What is the beta indicator for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Ultragenyx Pharmaceutical stock price target?

The target price for Ultragenyx Pharmaceutical (RARE) stock is $89.95, which is 112.3% above the current price of $42.37. This is an average based on projections from 19 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ultragenyx Pharmaceutical stock

Buy or sell Ultragenyx Pharmaceutical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing